01:47:54 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriMedicinteknik
Observe Medical är ett norskt bolag verksamma inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo.

Kalender

2022-11-03 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-03 Ordinarie utdelning OBSRV 0.00 NOK
2022-06-03 Kvartalsrapport 2022-Q1
2022-06-03 Årsstämma 2022
2022-03-29 Bokslutskommuniké 2021
2022-02-04 Extra Bolagsstämma 2022
2021-11-03 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning OBSRV 0.00 NOK
2021-05-21 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning OBSRV 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-16 Extra Bolagsstämma 2020
2020-05-12 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2022-01-14 07:02:34

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") earlier today, on 14 January 2022, regarding the resolution by the Company's board of directors to propose that the Company carries out a share capital increase, by way of a fully underwritten rights issue, to raise gross proceeds of NOK 180 million (the "Rights Issue").

Date on which the terms and conditions of the preferential rights issue were announced: 14 January 2022

Last day including right: 4 February 2022

Ex-date: 7 February 2022

Record Date: 8 February 2022

Date of approval: 4 February 2022

Maximum number of new shares: 180,000,000

Subscription price: Minimum NOK 1 and maximum NOK 30.00

Ratio preferential rights: To be announced when final number of new shares is determined

Subscription ratio: To be announced when final number of new shares is determined

Managers: Carnegie AS and DNB Markets, a part of DNB Bank ASA

Will the rights be listed: The Company will apply for listing of the preferential rights on Euronext Expand

ISIN for the preferential rights: To be announced when clarified

Other information: The subscription price for the new shares to be issued in the Rights Issue, and thus the exact number of new shares and the exact amount of the share capital increase, will be determined by the board of directors, based on a recommendation from the Managers, the day prior to the extraordinary general meeting to be held on 4 February 2022 (the "EGM"). See the stock exchange announcement containing the notice to the EGM published earlier today, on 14 January 2022, for further information regarding the Rights Issue. The rights issue is subject to approval by the EGM.

This information is published in accordance with the requirements of the Continuing Obligations.